ADMA Biologics (NASDAQ:ADMA) Given a $14.00 Price Target by Oppenheimer Analysts

Share on StockTwits

Oppenheimer set a $14.00 target price on ADMA Biologics (NASDAQ:ADMA) in a research note published on Tuesday, TipRanks reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

ADMA has been the topic of several other research reports. Jefferies Financial Group initiated coverage on shares of ADMA Biologics in a research note on Tuesday, June 4th. They set a buy rating and a $8.00 price objective on the stock. HC Wainwright set a $13.00 price target on shares of ADMA Biologics and gave the stock a buy rating in a research report on Thursday, May 23rd. WBB Securities raised shares of ADMA Biologics to a buy rating in a research report on Thursday, April 4th. ValuEngine raised shares of ADMA Biologics from a hold rating to a buy rating in a research report on Wednesday, April 3rd. Finally, Maxim Group set a $12.00 price target on shares of ADMA Biologics and gave the stock a buy rating in a research report on Tuesday, April 2nd. Nine equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of Buy and an average target price of $11.17.

ADMA stock traded down $0.04 during trading on Tuesday, reaching $3.59. 517,223 shares of the company were exchanged, compared to its average volume of 1,072,352. The stock has a market cap of $209.09 million, a P/E ratio of -2.48 and a beta of 2.93. ADMA Biologics has a 52-week low of $2.08 and a 52-week high of $6.96. The firm’s 50 day moving average is $4.16. The company has a current ratio of 4.60, a quick ratio of 2.39 and a debt-to-equity ratio of 5.70.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.01. ADMA Biologics had a negative net margin of 370.27% and a negative return on equity of 210.69%. The company had revenue of $3.53 million for the quarter, compared to the consensus estimate of $2.96 million. Equities analysts expect that ADMA Biologics will post -1.04 earnings per share for the current fiscal year.

In other ADMA Biologics news, Director Lawrence P. Guiheen acquired 25,000 shares of the stock in a transaction dated Friday, May 17th. The shares were bought at an average price of $4.00 per share, with a total value of $100,000.00. Following the purchase, the director now directly owns 50,000 shares of the company’s stock, valued at approximately $200,000. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Biotest Divestiture Trust sold 5,813,954 shares of ADMA Biologics stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $3.75, for a total transaction of $21,802,327.50. Following the completion of the transaction, the insider now directly owns 4,295,580 shares in the company, valued at approximately $16,108,425. The disclosure for this sale can be found here. In the last three months, insiders have acquired 4,064,500 shares of company stock worth $16,258,000. 18.80% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Diag Capital Management LP bought a new position in ADMA Biologics during the fourth quarter worth $435,000. JPMorgan Chase & Co. increased its position in ADMA Biologics by 54.7% during the third quarter. JPMorgan Chase & Co. now owns 228,999 shares of the biotechnology company’s stock worth $1,422,000 after acquiring an additional 81,003 shares during the period. Delek Group Ltd. increased its position in ADMA Biologics by 102.5% during the fourth quarter. Delek Group Ltd. now owns 118,539 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 60,000 shares during the period. Vanguard Group Inc. increased its position in ADMA Biologics by 5.2% during the third quarter. Vanguard Group Inc. now owns 1,192,641 shares of the biotechnology company’s stock worth $7,406,000 after acquiring an additional 58,610 shares during the period. Finally, Geode Capital Management LLC increased its position in ADMA Biologics by 14.4% during the fourth quarter. Geode Capital Management LLC now owns 276,930 shares of the biotechnology company’s stock worth $661,000 after acquiring an additional 34,818 shares during the period. 38.70% of the stock is currently owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Read More: Forex

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Novanta  Rating Lowered to Hold at BidaskClub
Novanta Rating Lowered to Hold at BidaskClub
BidaskClub Downgrades Malibu Boats  to Sell
BidaskClub Downgrades Malibu Boats to Sell
Materialise  Stock Rating Upgraded by BidaskClub
Materialise Stock Rating Upgraded by BidaskClub
Rio Tinto  Stock Rating Lowered by Renaissance Capital
Rio Tinto Stock Rating Lowered by Renaissance Capital
Credit Suisse Group Upgrades Ctrip.Com International  to Outperform
Credit Suisse Group Upgrades Ctrip.Com International to Outperform
AtriCure  Raised to “Buy” at Zacks Investment Research
AtriCure Raised to “Buy” at Zacks Investment Research


 
© 2006-2019 Zolmax.